Merck & Co., Inc. (NYSE:MRK) had its price target reduced by investment analysts at Credit Suisse Group from $66.00 to $65.00 in a note issued to investors on Wednesday. The firm presently has an “outperform” rating on the stock. Credit Suisse Group’s price target suggests a potential upside of 18.13% from the stock’s current price.
Other analysts also recently issued research reports about the company. JPMorgan Chase & Co. set a $70.00 price objective on Merck & Co., Inc. and gave the stock a “buy” rating in a research note on Sunday, October 29th. BMO Capital Markets set a $70.00 price objective on Merck & Co., Inc. and gave the stock a “buy” rating in a research note on Wednesday, October 18th. Citigroup raised Merck & Co., Inc. from a “neutral” rating to a “buy” rating and set a $72.00 price objective on the stock in a research note on Wednesday, October 18th. UBS Group reduced their price objective on Merck & Co., Inc. from $72.00 to $67.00 and set a “buy” rating on the stock in a research note on Monday, October 30th. Finally, Sanford C. Bernstein reaffirmed a “buy” rating and issued a $64.00 price objective on shares of Merck & Co., Inc. in a research note on Wednesday, November 15th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and eleven have issued a buy rating to the stock. Merck & Co., Inc. currently has a consensus rating of “Hold” and an average price target of $66.35.
Merck & Co., Inc. (NYSE MRK) traded up $0.12 during trading hours on Wednesday, reaching $55.02. The company’s stock had a trading volume of 5,601,214 shares, compared to its average volume of 14,688,156. The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.57. Merck & Co., Inc. has a 1-year low of $53.36 and a 1-year high of $66.80. The company has a market cap of $149,830.00, a P/E ratio of 59.16, a price-to-earnings-growth ratio of 2.49 and a beta of 0.75.
Merck & Co., Inc. declared that its board has authorized a stock buyback plan on Tuesday, November 28th that authorizes the company to buyback $10.00 billion in outstanding shares. This buyback authorization authorizes the company to reacquire shares of its stock through open market purchases. Shares buyback plans are often an indication that the company’s board believes its stock is undervalued.
In related news, insider Weir Mirian M. Graddick sold 5,000 shares of the business’s stock in a transaction on Friday, January 12th. The stock was sold at an average price of $58.00, for a total transaction of $290,000.00. Following the completion of the transaction, the insider now owns 101,484 shares in the company, valued at approximately $5,886,072. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Weir Mirian M. Graddick sold 60,000 shares of the business’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $61.63, for a total value of $3,697,800.00. Following the transaction, the insider now owns 101,484 shares of the company’s stock, valued at approximately $6,254,458.92. The disclosure for this sale can be found here. In the last three months, insiders have sold 82,500 shares of company stock worth $5,026,025. Corporate insiders own 0.25% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Krilogy Financial LLC lifted its holdings in shares of Merck & Co., Inc. by 0.4% in the 2nd quarter. Krilogy Financial LLC now owns 3,129 shares of the company’s stock worth $201,000 after buying an additional 11 shares during the period. Balentine LLC lifted its stake in shares of Merck & Co., Inc. by 1.0% during the 2nd quarter. Balentine LLC now owns 2,107 shares of the company’s stock worth $135,000 after purchasing an additional 20 shares during the last quarter. Jackson Grant Investment Advisers Inc. lifted its stake in shares of Merck & Co., Inc. by 0.4% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 9,291 shares of the company’s stock worth $595,000 after purchasing an additional 39 shares during the last quarter. Thompson Davis & CO. Inc. lifted its stake in shares of Merck & Co., Inc. by 0.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 4,313 shares of the company’s stock worth $276,000 after purchasing an additional 40 shares during the last quarter. Finally, Cornerstone Advisory LLP lifted its stake in shares of Merck & Co., Inc. by 0.4% during the 2nd quarter. Cornerstone Advisory LLP now owns 11,110 shares of the company’s stock worth $712,000 after purchasing an additional 43 shares during the last quarter. Institutional investors own 72.85% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Merck & Co., Inc. (MRK) Price Target Lowered to $65.00 at Credit Suisse Group” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/14/merck-co-inc-mrk-price-target-lowered-to-65-00-at-credit-suisse-group.html.
Merck & Co., Inc. Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.